The stock of Quince Therapeutics Inc (QNCX) has seen a -19.10% decrease in the past week, with a -17.51% drop in the past month, and a -39.90% decrease in the past quarter. The volatility ratio for the week is 8.72%, and the volatility levels for the past 30 days are at 9.03% for QNCX. The simple moving average for the past 20 days is -20.09% for QNCX’s stock, with a -33.45% simple moving average for the past 200 days.
Is It Worth Investing in Quince Therapeutics Inc (NASDAQ: QNCX) Right Now?
Additionally, the 36-month beta value for QNCX is 0.78. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for QNCX is 33.95M and currently, short sellers hold a 3.11% ratio of that float. The average trading volume of QNCX on May 15, 2025 was 260.08K shares.
QNCX) stock’s latest price update
Quince Therapeutics Inc (NASDAQ: QNCX)’s stock price has dropped by -11.43 in relation to previous closing price of 0.95. Nevertheless, the company has seen a loss of -19.10% in its stock price over the last five trading days. businesswire.com reported 2025-05-13 that SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $QNCX #biotech–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “In light of current cash runway and with the goal of maxim.
Analysts’ Opinion of QNCX
Many brokerage firms have already submitted their reports for QNCX stocks, with Oppenheimer repeating the rating for QNCX by listing it as a “Outperform.” The predicted price for QNCX in the upcoming period, according to Oppenheimer is $10 based on the research report published on March 24, 2025 of the current year 2025.
QNCX Trading at -30.26% from the 50-Day Moving Average
After a stumble in the market that brought QNCX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.66% of loss for the given period.
Volatility was left at 9.03%, however, over the last 30 days, the volatility rate increased by 8.72%, as shares sank -16.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.76% lower at present.
During the last 5 trading sessions, QNCX fell by -19.10%, which changed the moving average for the period of 200-days by +7.09% in comparison to the 20-day moving average, which settled at $1.0530. In addition, Quince Therapeutics Inc saw -55.01% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QNCX starting from Thye Dirk, who purchase 77,000 shares at the price of $0.70 back on Aug 30 ’24. After this action, Thye Dirk now owns 843,941 shares of Quince Therapeutics Inc, valued at $53,900 using the latest closing price.
Thye Dirk, the CEO AND CHIEF MEDICAL OFFICER of Quince Therapeutics Inc, purchase 77,500 shares at $0.69 during a trade that took place back on Aug 29 ’24, which means that Thye Dirk is holding 766,941 shares at $53,475 based on the most recent closing price.
Stock Fundamentals for QNCX
The total capital return value is set at -0.62. Equity return is now at value -130.90, with -45.58 for asset returns.
Based on Quince Therapeutics Inc (QNCX), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at -2.12.
Currently, EBITDA for the company is -56.55 million with net debt to EBITDA at -0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.05.
Conclusion
In conclusion, Quince Therapeutics Inc (QNCX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
